Literature DB >> 7863929

Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke.

S L Barnwell1, W M Clark, T T Nguyen, O R O'Neill, M L Wynn, B M Coull.   

Abstract

PURPOSE: To evaluate safety and efficacy of delayed intraarterial urokinase therapy with mechanical disruption of clot to treat thromboembolic stroke.
METHODS: Thirteen patients with cerebral thrombolic disease (10 carotid territory, 3 basilar territory) were treated with catheter-directed intraarterial urokinase therapy with mechanical disruption of the clots. All patients were excluded from a 6-hour multicenter thrombolytic trial by either time, recent surgery, age, seizure, or myocardial infarction. Time elapsed before treatment ranged from 3.5 to 48 hours (12 +/- 13 hours), with 200,000 to 900,000 U of urokinase used.
RESULTS: Ten patients had successful vessel recanalization, confirmed by repeat angiography. Cases with distal branch vessel occlusions were less likely to recanalize. Asymptomatic hemorrhagic conversion occurred in 2 patients on repeat scans. Both acute neurologic and functional outcomes were assessed with significant improvement occurring in 9 (69%) of 13 patients at 48 hours (greater than four-point change on the National Institutes of Health scale) and in 100% of 3-month survivors. All patients who improved had normal initial CT scans.
CONCLUSIONS: Intraarterial cerebral thrombolysis with mechanical disruption of clot seems to be a useful therapy in selected stroke cases even after 6 hours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7863929      PMCID: PMC8334278     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

Review 1.  Interventional neuroradiology.

Authors:  C M Strother
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

2.  Program requirements for residency/fellowship education in neuroendovascular surgery/interventional neuroradiology: a special report on graduate medical education.

Authors:  R T Higashida; L N Hopkins; A Berenstein; V V Halbach; C Kerber
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

3.  Intra-arterial thrombolysis.

Authors: 
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

Review 4.  Assessment of the interventional neuroradiology workforce in the United States: a review of the existing data.

Authors:  Harry J Cloft; Thomas A Tomsick; David F Kallmes; Jonas H Goldstein; John J Connors
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

5.  Is mechanical clot removal or disruption a cost-effective treatment for acute stroke?

Authors:  M N Nguyen-Huynh; S C Johnston
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-27       Impact factor: 3.825

6.  Site-specific thromboembolism: a novel animal model for stroke.

Authors:  Andrew J Ringer; Lee R Guterman; L Nelson Hopkins
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 7.  Recanalization therapy for acute ischemic stroke, part 1: surgical embolectomy and chemical thrombolysis.

Authors:  Saeed Ansari; Maryam Rahman; Michael F Waters; Brian L Hoh; J Mocco
Journal:  Neurosurg Rev       Date:  2010-11-24       Impact factor: 3.042

Review 8.  Mechanical interventions to treat acute stroke.

Authors:  David Fussell; H Christian Schumacher; Philip M Meyers; Randall T Higashida
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 9.  Management of acute ischemic stroke.

Authors:  Alex Abou-Chebl
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

10.  Intracranial aneurysms treated with Guglielmi detachable coils: midterm clinical and radiological outcome in 97 consecutive Chinese patients in Hong Kong.

Authors:  Simon C H Yu; Michael S Y Chan; Ronald Boet; Jeffrey K T Wong; Joseph M K Lam; Wai S Poon
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.